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Anticoagulation quality and clinical outcomes were compared between
the preintervention group (PRE) (05/01/2014–10/30/2014) and post-
intervention group (POST) (11/1/2014–04/30/2015) phases. The
primary endpoint was the time within the therapeutic international
normalized ratio (INR) range time in therapeutic range (TTR) as
calculated using the Roosendaal Linear interpolationmethod [4]. Bleed-
ing and thromboembolic events were deﬁned according to theKeywords:
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ThrombosisWhile continuous-ﬂow left-ventricular assist devices (CF-LVAD)
prolong survival in patients with heart failure who are refractory to
medical therapy [1], contemporary devices expose patients to a super-
posed risk of both thromboembolic and bleeding events [2,3]. Precise
anticoagulation management is therefore essential in mitigating these
potentially catastrophic complications. Historically at the Miami Trans-
plant Institute (MTI), anticoagulation was managed by specialized per-
sonnel, including LVAD coordinators, heart failure cardiologists, and
cardiothoracic surgeons. In November 2014, a multidisciplinary quality
improvement initiative at theMTI was devisedwith the aim of optimiz-
ing anticoagulation practice in ambulatory CF-LVADpatients. This initia-
tive consisted of establishing an anticoagulation management protocol,
standardizing INR target ranges, and integrating a clinical pharmacist as
a consultant into the care team. The objective of this report is to evaluate
the ability of the initiative to improve anticoagulation control in CF-
LVAD patients compared to a historical control cohort.al Center, 622 W. 168th Street,
ed States.
.L. Jennings).
.This study enrolled all CF-LVAD patients whose anticoagulation
was managed at our center between May 2014 and April 2015.
INTERMACS criteria [5]. Each patient had to be included in both the
PRE and POST phase in order to serve as their own control. Differences
in TTR and bleeding/thromboembolic events between the PRE and
POST cohorts were analyzed with a paired t-test or chi-square test,
respectively using SPSS version 22.0 (IBM Corporation). The study pro-
tocol conforms to the ethical guidelines of the 1975 Declaration of
Helsinki as reﬂected in a priori approval by our institution's human re-
search committee with waiver of informed consent (given the retro-
spective nature of the work).
Thirty-three patients (age 51 years, male 84.8%, BTT 45.5%,
HeartMate II [HMII] 72.7%) from May 2014 to April 2015 yielded 1675
INR values with 10,618 days of follow-up (5419 days, PRE group;
5199 days, POST group). The average TTR in the PRE group was
29.7 ± 11.1%, which increased to 60 ± 21.4% in the POST group
(p b 0.001) (Table 1). TTR in the POST patients was numerically higher
in those with the HMII device relative to HeartWare HVAD (64± 19.9%
vs 49.8 ± 23.1%, respectively; p= 0.092). Rates of bleeding and throm-
boembolic complications were similar between the PRE and POST
groups (Table 1).
Previous data have established the beneﬁt of a pharmacist-driven
clinic for managing ambulatory non-LVAD patients receiving warfarin-
based anticoagulation [6]. Bishop et al. demonstrated a signiﬁcant im-
provement in TTR after the implementation of a pharmacist-managed
anticoagulation clinic coupled with patient INR self-testing in a small
cohort of CF-LVAD patients [7]. While these ﬁndings are certainly posi-
tive, not all LVAD centers have the resources to deploy full-time
pharmacist-managed anticoagulation services, and the availability of
patient INR testing can be limited by insurance coverage. Our study
Table 1
Anticoagulation quality and clinical outcomes.
Variable Pre-intervention
(n = 33)
Post-intervention
(n = 33)
p-Value
Anticoagulation control
Time in therapeutic range (%) 29.7 ± 11.1 60.0 ± 21.4 b0.001
Time INR ≤ 1.5 (days) 5.3 ± 8.6 3.0 ± 6.0 0.138
Time INR ≥ 4.0 (days) 5.4 ± 6.8 5.0 ± 7.8 0.766
Clinical outcomes
Patients with bleeding event 4 (12.1) 3 (9.1) 0.689
Number of bleeding events (all
gastrointestinal bleeding)
7 4 0.52
Average INR at time of bleed 3.26 2.7
Patients with TE events 3a (9.1) 4b (12.1) 0.689
Number of TE events 6 5 1.00
Stroke 2 1
Pump thrombosis 3 4
Minor hemolysis 1 1
Major hemolysis 2 3
Pump exchange 1 0
Other 1c
Average INR at time of TE 2.826 2.76
INR = international normalized ratio; TE = thromboembolic.
a One patient had a transient ischemic attack (TIA) and twomajor hemolysis events, one
patient had a stroke and a ventricular thrombus, and one patient had a minor hemolysis
event.
b One patient had one minor and one major hemolysis event, one patient had a stroke
and two patients each had a major hemolysis event.
c Ventricular thrombus.
119Correspondencewas able to show that marked improvement in TTR is possible in LVAD
patients without the use of a dedicated anticoagulation clinic. The aver-
age TTR in our POST group (60%) was actually higher than previous
LVAD cohorts managed by these traditional models, including those re-
ported by Bishop et al.[7] (44%) and Jennings et al.[8] (51%).
This noteworthy improvement was likely due to the multifaceted
nature of our intervention, which included deployment of standardized
target INR ranges, use of warfarin dosing algorithms, less frequent INR
monitoring in stable patients, enhanced drug–drug interaction screen-
ing, and clinical pharmacist consultation for out-of-range values. De-
spite improving TTR, there was no difference in the rate of clinical
endpoints between the PRE and POST groups in our study. These ﬁnd-
ings are likely due to the small sample size and the low rate of bleeding
and thrombotic complications during the study period. Despite this lim-
itation, recent literature has demonstrated that poor INR control (TTR
less than 50%) in CF-LVAD patients is associated with a nearly 3 fold in-
creased risk of thromboembolic complications [9], which suggests thatTTR may be a valid surrogate endpoint for anticoagulation quality in
this patient population.
Our ﬁndings must be viewed in the context of a single center retro-
spective analysis with a relatively small sample size and follow-up
period. Despite these limitations, this study demonstrated that an out-
patient multidisciplinary anticoagulation quality improvement initia-
tive can be successfully implemented in a CF-LVAD population
without the establishment of a traditional anticoagulation clinic. This
model is desirable particularly in institutions where patients are geo-
graphically dispersed and resources may be limited. Future studies are
warranted to determine the reproducibility of these ﬁndings in a larger
patient population.
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